Clinical Study

A Phase III, Multicentre, Randomised, Double-Blind, Controlled Study To Investigate The Efficacy, Safety, And Tolerability Of Two Administrations Of Comp360 In Participants With Treatment-Resistant Depression

Posted Date: Dec 12, 2022

  • Investigator: Fabiano Nery
  • Specialties:
  • Type of Study: Drug

To investigate the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.


Aged =18 Years At Screening, Trd, Defined As Failure To Respond To An Adequate Dose And Duration Of Two, Three, Or Four Different Pharmacological Treatments For The Current Episode,


Depression, Adults With Trd, Psilocybin Therapy

For More Information:

Colette Mueller, M.A.
513 – 558 – 5059

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.